

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: NC20170004535 Fecha de prioridad: 10 de octubre de 2014				
CRITERIOS PARA LA BÚSQUEDA				
Palabras clave utilizadas		Macrocyclic AND peptides AND PD-1/PD-L1 AND PD-L1/CD80 AND interaction AND cancer AND infect* AND (A61K38/12 OR C07K7/52 OR C07K7/56 OR G01N33/68)		
		Macrocyclic AND peptides AND PD-1/PD-L1 AND PD-L1/CD80 AND interaction AND cancer AND infect*		
		Macrocyclic AND peptides AND PD-1 AND PD-L1 AND CD80 AND interaction AND cancer AND infect*		
		Macrocyclic* AND péptidos AND PD-1/PD-L1 AND PD-L1/CD80 AND interacción AND cáncer AND infec* AND (A61K38/12 OR C07K7/52 OR C07K7/56 OR G01N33/68)		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: C07K 7/52, C07K 7/56, A61K 38/12, G01N 33/68		
DOCUMENTOS CONSIDERADOS RELEVANTES				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	Ninguna	---	---	---
ISA/IPEA (EPO US) Espacenet	WO2014151634	25/09/2014	1-8 (Ejs 9018-9021 y reiv 1)	X, Y
	(*)	01/08/1980	1-8 pags 5502 - 5505	X, Y
USPTO	No hicieron búsqueda			
Patbase	WO2014151634	25/09/2014	1-8 (Ejs 9018-9021 y reiv 1)	X, Y
Google Patents	WO2014151634	25/09/2014	1-8 (Ejs 9018-9021 y reiv 1)	X, Y
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
Literatura no patente **Se incluye entre otros, toda la referencia de la literatura no patente.		(*) WILLIAM J. COOK ET AL, "Crystal structure and conformation of the cyclic trimer of a repeat pentapeptide of elastin, cyclo-(L-valyl-L-prolylglycyl-L-valylglycyl)3", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, US, (19800801), vol. 102, no. 17, doi:10.1021/ja00537a014, ISSN 0002-7863, pags 5502 - 5505, XP055228682 [X] 1,4 * fig 2		
Fecha del reporte de búsqueda:		23 de julio de 2018		

SIPI:

Título/Denominación	tidos AND PD-1/PD-L1 AND PD-L1/CD80 AND interacción AND cáncer AND infec* AND (A61K38/12 OR C07K7/52 OR C07K7/56 OR G01N33/68)	
Referencia del solicitante		Tipo de solicitud ▼
Fecha de radicación	Advertencia(s) Su búsqueda no produjo resultados. Ok	
Decision Date_ES		
Título/Denominación	Macro* AND péptidos AND cáncer AND infec*	
Referencia del solicitante		Tipo de solicitud ▼
Fecha de radicación	Advertencia(s) Su búsqueda no produjo resultados. Ok	
Decision Date_ES		

EPO:

MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS


Page 1313/1343 Claims Maximise Document too large

WO 2014/151634

PCT/US2014/026138

WHAT IS CLAIMED IS:


1. A compound of formula (I)



(I),

or a pharmaceutically acceptable salt thereof, wherein:

A is selected from a bond,



Article

Previous Article Next Article Table of Contents

Crystal structure and conformation of the cyclic trimer of a repeat pentapeptide of elastin, cyclo-(L-valyl-L-prolylglycyl-L-valylglycyl)₃

William J. Cook, Howard Einspahr, Tina L. Trapane, Dan W. Urry, and Charles E. Bugg

J. Am. Chem. Soc., **1980**, *102* (17), pp 5502–5505

DOI: 10.1021/ja00537a014

Publication Date: August 1980

ACS Legacy Archives

Cite this: *J. Am. Chem. Soc.* **102**, *17*, 5502–5505

RIS Citation GO

Note: In lieu of an abstract, this is the article's first page.

5502 *J. Am. Chem. Soc.* **1980**, *102*, 5502–5505

are not likely to be directly affected by surface chemical effects. The recombination lifetime of electrons at the semiconductor surface is critical to the kinetics of photocatalytic reductions. This lifetime can be increased by the presence of hole-acceptor surface states which are themselves inefficient recombination centers.¹⁾ Adsorbed hydroxide could form such surface states. The quantum efficiency for reduction would then increase with the surface hydroxide concentration which, under steady-state conditions, depends on the rate of surface rehydroxylation. Hydroxide-induced band bending and inhibition of recombination at the surface probably both play a role in the kinetics of photoelectrochemical cells operated at zero applied potential, where band bending is

minated yielded hydrogen at readily measurable rates. Schrauzer and Guth²⁾ have reported the photodissociation of water on TiO₂ powders. However, the process stopped within several hours and could not be sustained to produce catalytic amounts of hydrogen. As discussed in the Experimental Section, product yields, to serve as a criterion for catalytic activity, should be normalized to the total surface area of the catalyst. Using the high end of their reported 0.5–1-μm particle size range and assuming spherical particles, they observed the maximum hydrogen accumulation corresponding to ~ two monolayers. The ion-transport problems associated with photoelectrochemical reactions in the gas phase have already been discussed. We



Article Options

PDF (488 KB)

PDF w/ Links (0 KB)

Abstract

Supporting Info

Citing Articles

Add to Favorites

Download Citation

Email a Colleague

Order Reprints

Rights & Permissions

Citation Alerts

Add to ACS ChemWorx

Search 3: Macrocytic AND peptides AND PD-1 AND PD-L1 AND CD80 AND interaction AND cancer AND infect*
Results 11

Explore search

#	Search query	Results	Options
3	Macrocytic AND peptides AND PD-1 AND PD-L1 AND CD80 AND interaction AND cancer AND infect*	11	View Browse Hits Optimise more...
2	Macrocytic AND peptides AND PD-1/PD-L1 AND PD-L1/CD80 AND interaction AND cancer AND infect*	0	
1	Macrocytic AND peptides AND PD-1/PD-L1 AND PD-L1/CD80 AND interaction AND cancer AND infect* AND (A61K38/12 OR C07K7/52 OR C07K7/56 OR G01N33/68)	0	

Google Patents:

Macrocytic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 ...

www.google.com.co/patents/WO2014151634A1?cl=en

Solicitud - Presentada el 13/03/2014 - Publicada el 25/09/2014 - Michael Matthew Miller - Bristol-Myers Squibb Company

The interaction between PD-1 and PD-L1 results in a decrease in tumor of chronic infection (Ha, S.J. et al, "Enhancing therapeutic vaccination by blocking PD-1 ... The macrocytic peptides described herein are capable of inhibiting the ...

Descripción general · Información relacionada · Debatir

Macrocytic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 ...

www.google.com.co/patents/US20160340391

Solicitud - Presentada el 7/07/2016 - Publicada el 24/11/2016 - Michael Matthew Miller - Bristol-Myers Squibb Company

... thus are useful for the amelioration of various diseases, including cancer and infectious diseases. ... Humanized mice infected with HIV-1 show enhanced protection ... Blockade of the PD-L1/CD80 interaction has also been shown to ... The macrocytic peptides described herein are capable of inhibiting ...

Descripción general · Información relacionada · Debatir

Macrocytic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 ...

www.google.com.co/patents/CA2905453A1?cl=en

Solicitud - Presentada el 13/03/2014 - Publicada el 25/09/2014 - Michael Matthew Miller - Bristol-Myers Squibb Company

The interaction between PD-1 and PD-L1 results in a decrease in tumor ... of tumors and chronic infections have shown that blockade of the PD-1/PD-L1 pathway by ... The macrocytic peptides described herein are capable of inhibiting the ...

Descripción general · Información relacionada · Debatir